查看文章

The nucleocapsid protein (NP) of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) contains immunogenic epitopes that can induce cytotoxic T lymphocyte (CTL) against viral infection. This makes the nucleocapsid protein a suitable candidate for developing a vaccine against SARS‐CoV‐2 infection. This article reports the intradermal delivery of NP antigen using dissolvable microneedle skin patches that could induce both significant B cell and T cell responses.